Natera

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The firm also offers Constellation, a cloud-based software product that allows laboratory customers to gain access to the algorithms and bioinformatics in order to validate and launch tests based on the technology. The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Natera reports robust Q4 results, eyes growth in genetic testing

Natera's Q4 2022 performance reflects strong growth in tests and revenues, particularly in oncology, setting the stage for future success.
The company's strategic milestones, new board appointment, and focus on clinical business growth highlight its resilience and market leadership.
While facing challenges in cost management and market competition, Natera has opportunities to leverage positive industry trends and policy changes for sustained growth.

Natera posts strong Q1 results, focuses on clinical differentiation

Natera's Q1 earnings call highlighted robust financials, strategic focus on clinical differentiation, and efforts to improve margins through ASP and COGS projects. Despite challenges with ASP and gross margins, the company remains optimistic about its trajectory and growth opportunities in women's health and organ health.

Natera reports stellar Q2 results, eyes growth amid regulatory changes

Natera delivered a strong Q2 performance with robust revenue growth, improved margins, and strategic advancements across oncology, women's health, and organ health segments.
The company showcased strengths in clinical utility, peer-reviewed publications, and litigation victories, while also addressing challenges like pricing pressures and regulatory changes.
Opportunities lie in expanding market reach through ACOG meetings, commercial coverage enhancements, and leveraging competitor exits for growth in carrier testing business.
Overall, Natera's revised guidance, financial outperformance, and focus on innovation position the company for continued success and market leadership in the genomics space.

Natera (NTRA) reports robust Q3 earnings, eyes market expansion

Natera (NTRA) delivered strong financial performance in Q3 2023, with raised revenue guidance and improved cash burn guidance.
The company's focus on achieving cash flow breakeven in 2024 while driving innovation and market engagement highlights a strategic growth trajectory.
While facing challenges such as pending lawsuits and regulatory uncertainties, Natera is well-positioned to capitalize on opportunities like market expansion and product innovation.

Natera reports robust earnings, eyes growth through strategic acquisitions

Natera's strong financial performance, strategic acquisitions, and focus on key developments position the company for continued growth.
While challenges like maintaining ASP trends and managing competition exist, opportunities in revenue growth, clinical studies, and guideline expansions offer potential upside.
Careful execution, volume growth, and momentum will be crucial for Natera's success in 2024, supported by confidence in their guidelines and innovative testing approaches.

Natera excels in Q1, eyes revenue growth and margin improvement

Natera's Q1 performance was outstanding, marked by revenue growth, margin expansion, and progress in key clinical areas.
While challenges like replicating exceptional performance and seasonal dips exist, the company is well-positioned for future growth.
Opportunities lie in improving margins, volume growth, and market penetration, supporting Natera's ambitious revenue targets.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.

AUSTIN, Texas--( BUSINESS WIRE )--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication of a new paper in Pediatric Nephrology, which highlights the clinical utility of Renasight™ in aiding the diagnosis and management of kidney disease. The publication can be found here.

New Paper Highlights Clinical Utility of Natera's Renasight™ Test in the Management of Kidney Disease

AUSTIN, Texas--( BUSINESS WIRE )--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, will be presented at the American Society of Clinical Oncology's 2023 Gastrointestinal Cancers Symposium (ASCO GI), taking place January 19 – 21, 2023 in San Francisco, California. The presentations will highlight findings on the utility of Signatera for MRD assessment in colorectal (CRC), esophageal, gastric and anal cancers, in a total of five presentations.

New Signatera™ MRD Data in Gastrointestinal Cancers to be Presented at the ASCO GI Symposium 2023

AUSTIN, Texas--( BUSINESS WIRE )--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication of a new study in Nature Medicine, which demonstrates the ability of the SignateraTM molecular residual disease (MRD) test to identify patients with stage II-IV colorectal cancer (CRC) who are at an increased risk of recurrence and predict who is likely to benefit from adjuvant chemotherapy (ACT). With this study, data supporting the clinical validity and utility of Signatera has now been published in 40 peer-reviewed publications.

Natera Announces Publication of Prospective, Multi-Site CIRCULATE Study in Nature Medicine Demonstrating Signatera's Ability to Predict Chemotherapy Benefit in Colorectal Cancer

The average of price targets set by Wall Street analysts indicates a potential upside of 82.9% in Natera (NTRA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think Natera (NTRA) Could Surge 82.88%: Read This Before Placing a Bet

AUSTIN, Texas--( BUSINESS WIRE )--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will webcast a live presentation at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 10, 2023 at 9:45 a.m. PT (12:45 p.m. ET).

Natera to Webcast Live Presentation at the 41st Annual J.P. Morgan Healthcare Conference

AUSTIN, Texas--( BUSINESS WIRE )--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, announced its support for a recent guideline update by the International Society for Heart and Lung Transplantation (ISHLT), which includes the use of donor-derived cfDNA (dd-cfDNA) testing for surveillance of heart transplant recipients. The updated ISHLT guidelines, which were last revised in 2010, were published today in the Journal of Heart and Lung Transplantation1 .

Natera Supports Updated ISHLT Guidelines for the Care of Heart Transplant Patients

Natera, Inc. is doubling down on its growth initiatives to expand its product portfolio beyond the non-invasive prenatal testing market. The company's growth initiatives highlight strategic discrepancies between the Texas-based molecular diagnostic company and its peers, with clearer profitability paths.

Natera's Worrisome Cash Burn

Across all subtypes, in a real-world cohort of >200 patients and >900 plasma samples, the presence of ctDNA at any time was strongly associated with disease recurrence and poor prognosis AUSTIN, Texas , Dec. 9, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication of a new study in JCO Precision Oncology highlighting the clinical utility of its personalized and tumor-informed molecular residual disease test, Signatera™, for postoperative risk stratification and prediction of recurrence in patients with stage I-III esophageal and gastric cancers (EGCs). The full study can be found here.

Natera Announces Publication of Multi-Center Study Validating Signatera's Ability to Predict Recurrence in Esophageal and Gastric Cancers

AUSTIN, Texas , Dec. 7, 2022 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a global leader in cell-free DNA testing, plans to present new clinical data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, and its hereditary cancer test, Empower, at the 2022 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas. Natera will present two posters from the LEADER and I-SPY 2 clinical trials in HR+, HER2- breast cancer highlighting Signatera's ability to detect recurrence and facilitate treatment response monitoring.

Natera to Present New Signatera™ and Empower™ Data at the 2022 Annual San Antonio Breast Cancer Symposium

Study aligns with Natera's longstanding commitment to generate robust, real-world clinical evidence and highlights unique capabilities of Panorama SNP-based NIPT AUSTIN, Texas , Dec. 6, 2022 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication in Prenatal Diagnosis of a clinical experience study in twin pregnancies featuring its Panorama single nucleotide polymorphism (SNP)-based noninvasive prenatal test (NIPT). These real-world results are consistent with previously reported performance of NIPT in twins, and reinforce the importance of Panorama's unique ability to determine zygosity and incorporate this information into risk assessments.

Natera Announces Publication of Clinical Experience Study with 18,984 Twin Pregnancies Supporting Excellent Performance of Panorama™ NIPT

AUSTIN, Texas , Nov. 23, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Steve Chapman, chief executive officer, and Mike Brophy, chief financial officer, will be presenting at the Piper Sandler 34th Annual Healthcare Conference located at the Lotte New York Palace on Wednesday, November 30 at 12:00 p.m. PT (3:00 p.m.

Natera to Participate in the Piper Sandler 34th Annual Healthcare Conference

ctDNA reduction at week nine in patients treated with tebentafusp was associated with improved overall survival AUSTIN, Texas , Nov. 21, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication of a new study in Nature Medicine, which shows that its mPCR technology is able to assess response to tebentafusp in treatment-refractory metastatic uveal melanoma. The findings indicated an association between early reductions in ctDNA and longer overall survival, suggesting that traditional radiographic-based response criteria don't accurately reflect tebentafusp-related clinical activity and benefit.

New Published Study Further Demonstrates the Ability of Natera's mPCR Technology to Monitor Immunotherapy Response in Metastatic Uveal Melanoma Patients

AUSTIN, Texas , Nov. 15, 2022 /PRNewswire/ -- Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the pricing of its underwritten public offering of 11,430,000 shares of its common stock at a price to the public of $35.00 per share. Closing of the offering is expected to occur on November 18, 2022, subject to customary closing conditions.

Natera Announces Pricing of Follow-On Offering

Natera, Inc. (NASDAQ:NTRA ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Michael Brophy - Chief Financial Officer Steve Chapman - Chief Executive Officer Solomon Moshkevich - General Manager, Oncology Conference Call Participants Puneet Souda - SVB Securities Tejas Savant - Morgan Stanley Max Masucci - Cowen Julia Qin - JPMorgan Catherine Schulte - Baird Operator Welcome to Natera's 2022 Third Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Natera, Inc. (NTRA) Q3 2022 Earnings Call Transcript

Natera (NTRA) delivered earnings and revenue surprises of 11.97% and 1.12%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Natera (NTRA) Reports Q3 Loss, Tops Revenue Estimates

AUSTIN, Texas , Nov. 8, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the third quarter ended September 30, 2022. Recent Strategic and Financial Highlights Generated total revenues of $210.6 million in the third quarter of 2022 compared to $158.1 million in the third quarter of 2021, an increase of 33.2%.

Natera Reports Third Quarter 2022 Financial Results

AUSTIN, Texas , Nov. 2, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it was awarded a nationwide contract, effective Sept. 15, 2022, with the U.S. Department of Veterans Affairs (VA) National Precision Oncology Program, to provide minimal residual disease (MRD) and monitoring services with the company's personalized and tumor-informed MRD test, Signatera™.

Natera Awarded National MRD Testing Contract by the U.S. Department of Veterans Affairs

AUSTIN, Texas , Nov. 1, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Steve Chapman, chief executive officer, and Mike Brophy, chief financial officer, will be presenting at the Credit Suisse 31st Annual Healthcare Conference on Wednesday, November 9 at 10:25 a.m. PT (1:25 p.m.

Natera to Participate in Credit Suisse 31st Annual Healthcare Conference

AUSTIN, Texas , Nov. 1, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced it will release results for its third quarter ended September 30, 2022, after the market closes on November 8, 2022. Natera will host a conference call and webcast at 1:30 p.m.

Natera to Report its Third Quarter 2022 Results on November 8th

Media reports of dramatic consequences of incorrect gene test interpretation and use combined with allegations of aggressive billing tactics drove the NTRA shares reeling. This negative publicity alienated investors who seem to miscalculate its impact on NTRA's revenue, opening an opportunity for contrarian traders as the company continues executing its growth strategy.

Natera: Cracks In The Bearish Trade

Multi-site study shows personalized ctDNA analysis is highly prognostic of recurrence-free survival and outperforms CA-125 in identifying patients at high risk of recurrence AUSTIN, Texas , Oct. 6, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication of a manuscript in Gynecologic Oncology, found here , validating the performance of its personalized molecular residual disease (MRD) test, Signatera, in epithelial ovarian cancer (EOC). This study adds to the growing library of over 30 published clinical studies incorporating Signatera technology.

New Publication Validates Performance of Natera's Signatera™ MRD Test in Ovarian Cancer

AUSTIN, Texas , Oct. 4, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of the latest data from the Trifecta study in Transplantation, found here .  The investigators found that in predicting antibody mediated rejection (AMR), donor-derived cell-free DNA (dd-cfDNA) testing with the Prospera Kidney test was superior to the current standard of care, donor-specific antibody (DSA) testing.

Trifecta Study Demonstrates Prospera™ Kidney dd-cfDNA Test Outperforms DSA in Predicting Antibody Mediated Rejection

AUSTIN, Texas , Sept. 29, 2022 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of its 2021 Environmental, Social and Governance (ESG) report detailing the company's commitment to environmental sustainability, social equity and improved access to health care.

Natera Announces 2025 ESG Goals with Publication of 2021 Report

Data from the largest real-world MRD study to date in resectable colorectal cancer reinforces the findings from the recent CIRCULATE-Japan study AUSTIN, Texas , Sept. 12, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera™, at the 2022 European Society for Medical Oncology (ESMO) World Congress, taking place September 9-13 in Paris, France.

Natera Presents New Colorectal and Breast Cancer Data at ESMO 2022, Highlighting Signatera's Ability to Inform Treatment Decisions in the Adjuvant and Neoadjuvant Settings

AUSTIN, Texas , Aug. 25, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, is proud to be certified by Great Place to Work® for the second consecutive year. The certification is based entirely on how current employees rate their experience working at Natera in an independently administered, anonymous survey.

News for Natera Stock (NTRA)